Novo Nordisk A/S (NVO) Receives $55.00 Consensus Price Target from Brokerages

Zacks Investment Research lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, July 17th. The rating was upgraded by Credit Suisse to “Outperform” on Wednesday, August 19. Novo Nordisk A/S now has a consensus rating of “Hold” and a consensus price target of $55.00. Morgan Stanley downgraded it to “Underweight” rating and $126 target in Tuesday, April 11 report. More interesting news about Novo Nordisk A S (ADR) (NYSE:NVO) were released by: and their article: “Tuesday’s Vital Data: Teva Pharmaceutical Industries Ltd (ADR) (TEVA), Snap …” published on September 12, 2017 as well as’s news article titled: “Why Novo Nordisk A/S Got Crushed Today” with publication date: October 28, 2016. The firm has “Neutral” rating by Piper Jaffray given on Friday, September 23. The firm has “Neutral” rating given on Wednesday, September 6 by Bank of America. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have assigned a buy rating to the company’s stock. The rating was downgraded by DNB Markets on Monday, October 31 to “Hold”. The firm has “Hold” rating given on Friday, August 28 by Zacks.

Harbour Investment Management LLC purchased a new position in Novo Nordisk A/S (NYSE:NVO) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). Tekla Capital Management Llc bought 134,300 shares as the company’s stock rose 15.20% with the market. The Alta Capital Management Llc holds 882,233 shares with $37.84M value, down from 922,362 last quarter. Salesforce Com Inc now has $68.29B valuation. The stock decreased 1.26% or $1.33 on September 22, reaching $104.59. With short interest at 3,345,534 and short average daily volume at 1,748,879, the short-interest ratio is 2.0 and the percentage of shorted shares is 0.00% as of August 31. Quad Graphics, Inc. (NYSE:QUAD) has risen 28.76% since September 23, 2016 and is uptrending. It has underperformed by 8.92% the S&P500.

Shares of Novo Nordisk A/S (NYSE NVO) traded up 0.33% during mid-day trading on Friday, hitting $49.22. About 795,458 shares traded.

Media coverage about Novo Nordisk A/S (NYSE:NVO) has trended somewhat positive on Saturday, Accern reports. It has underperformed by 40.63% the S&P500. Novo Nordisk A/S’s dividend payout ratio (DPR) is now 36.44%. Renaissance Technologies Llc who had been investing in Novo for a number of months, seems to be less bullish one the $96.23 billion market cap company. It has a 14.32 P/E ratio. The corporation operates through two firm segments: diabetes and obesity care, and biopharmaceuticals. the firms diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. $3.91 million worth of stock was sold by AHRENDTS ANGELA J on Tuesday, May 9. $866,418 worth of, inc. (NYSE:QUAD) was sold by Blais David A. Wojcicki Susan bought 1,154 shares worth $99,987. Next Financial Group, Inc downsized its ownership by shedding 400 shares a decrease of 8.4%. SEWELL D BRUCE sold $10.04M worth of stock. After having $0.59 EPS previously, Novo Nordisk A S (ADR)’s analysts see -1.69% EPS growth. Therefore 100% are positive. had 153 analyst reports since August 21, 2015 according to SRatingsIntel. On Monday, February 15 the stock rating was upgraded by Goldman Sachs to “Conviction Buy”. The company was upgraded on Tuesday, December 6 by UBS. They set an “underweight” rating for the company. The rating was maintained by Jefferies with “Sell” on Thursday, August 27. Penobscot Mgmt Com holds 2.05% in Apple Inc. (NYSE:CRM) to report earnings on November, 16. As of the last earnings report the EPS was $2.47 and is estimated to be $2.46 for the current year with 2,480,199,000 shares now outstanding. NVO’s profit would be $1.13 billion giving it 21.21 P/E if the $0.58 EPS is correct.

Investors sentiment increased to 0.68 in Q2 2017. (ECHO) stake by 12.24% reported in 2017Q2 SEC filing. It also reduced its holding in Sanofi (NYSE:SNY) by 125,100 shares in the quarter, leaving it with 179,900 shares, and cut its stake in Pfizer Inc. Its up 0.04, from 0.64 in 2017Q1. Amgen Inc (NASDAQ:AMGN) was reduced too. 129 funds opened positions while 634 raised stakes. Invesco reported 905,756 shares. Ithaka Group Llc reported 344,295 shares. (NASDAQ:ECHO). Fenimore Asset holds 396,750 shares or 0.33% of its portfolio.

Leave a Reply

Your email address will not be published. Required fields are marked *